Literature DB >> 21205400

The generic drug market in Japan: will it finally take off?

Toshiaki Iizuka1, Kensuke Kubo.   

Abstract

Historically, brand-name pharmaceuticals have enjoyed long periods of market exclusivity in Japan, given the limited use of generics after patent expiration. To improve the efficiency of the health-care system, however, the government has recently implemented various policies aimed at increasing generic substitution. Although this has created expectations that the Japanese generic drug market may finally take off, to date, generic usage has increased only modestly. After reviewing the incentives of key market participants to choose generics, we argue that previous government policies did not provide proper incentives for pharmacies to boost generic substitution. We offer some recommendations that may help to increase generic usage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21205400     DOI: 10.1017/S1744133110000332

Source DB:  PubMed          Journal:  Health Econ Policy Law        ISSN: 1744-1331


  3 in total

1.  Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan.

Authors:  Jörg Mahlich; Masamichi Nishi; Yoshimichi Saito
Journal:  Clinicoecon Outcomes Res       Date:  2015-05-22

2.  The changing patterns of dispensing branded and generic drugs for the treatment of gastroesophageal reflux disease between 2006 and 2011 in Japan: a retrospective cohort study.

Authors:  Kyoko Murata; Shiro Hinotsu; Shota Hamada; Yasumasa Ezoe; Manabu Muto; Koji Kawakami
Journal:  BMC Health Serv Res       Date:  2015-02-27       Impact factor: 2.655

3.  Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate.

Authors:  Jeewon Park; SeungJin Bae; Tae-Jin Lee; Kyung-Bok Son
Journal:  Front Pharmacol       Date:  2020-03-06       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.